A Randomized, Double-Blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-Dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects